Implications of Population-level Immunity for the Emergence of Artemisinin-resistant Malaria: a Mathematical Model
Overview
Authors
Affiliations
Background: Artemisinin-resistant Plasmodium falciparum has emerged in the Greater Mekong Subregion, an area of relatively low transmission, but has yet to be reported in Africa. A population-based mathematical model was used to investigate the relationship between P. falciparum prevalence, exposure-acquired immunity and time-to-emergence of artemisinin resistance. The possible implication for the emergence of resistance across Africa was assessed.
Methods: The model included human and mosquito populations, two strains of malaria ("wild-type", "mutant"), three levels of human exposure-acquired immunity (none, low, high) with two types of immunity for each level (sporozoite/liver stage immunity and blood-stage/gametocyte immunity) and drug pressure based on per-capita treatment numbers.
Results: The model predicted that artemisinin-resistant strains may circulate up to 10 years longer in high compared to low P. falciparum prevalence areas before resistance is confirmed. Decreased time-to-resistance in low prevalence areas was explained by low genetic diversity and immunity, which resulted in increased probability of selection and spread of artemisinin-resistant strains. Artemisinin resistance was estimated to be established by 2020 in areas of Africa with low (< 10%) P. falciparum prevalence, but not for 5 or 10 years later in moderate (10-25%) or high (> 25%) prevalence areas, respectively.
Conclusions: Areas of low transmission and low immunity give rise to a more rapid expansion of artemisinin-resistant parasites, corroborating historical observations of anti-malarial resistance emergence. Populations where control strategies are in place that reduce malaria transmission, and hence immunity, may be prone to a rapid emergence and spread of artemisinin-resistant strains and thus should be carefully monitored.
Woldesenbet D, Birhanie M, Abere A, Zeleke A, Bezabih M, Semaw M Malar J. 2024; 23(1):266.
PMID: 39215366 PMC: 11363363. DOI: 10.1186/s12936-024-05082-y.
Indigenous emergence and spread of C469Y artemisinin-resistant in Uganda.
Awor P, Coppee R, Khim N, Rondepierre L, Roesch C, Khean C Antimicrob Agents Chemother. 2024; 68(8):e0165923.
PMID: 39028193 PMC: 11304714. DOI: 10.1128/aac.01659-23.
Amadi M, Erandi K BMC Infect Dis. 2024; 24(1):664.
PMID: 38961345 PMC: 11220975. DOI: 10.1186/s12879-024-09570-z.
Behrens H, Schmidt S, Henshall I, Lopez-Barona P, Peigney D, Sabitzki R mBio. 2024; 15(6):e0198123.
PMID: 38700363 PMC: 11237660. DOI: 10.1128/mbio.01981-23.
Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea.
Mihreteab S, Platon L, Berhane A, Stokes B, Warsame M, Campagne P N Engl J Med. 2023; 389(13):1191-1202.
PMID: 37754284 PMC: 10539021. DOI: 10.1056/NEJMoa2210956.